抗抑郁药与抗精神病药副作用及个体化处方:系统综述与数字工具开发
该伞状综述检索Embase、PsycINFO和MEDLINE自建库至2023年6月26日的文献,纳入14篇文章(含68项单药副作用meta分析)并复习19部指南,构建了32种抗精神病药(14类副作用)和37种抗抑郁药(9类副作用)的副作用数据库,并据此开发Psymatik Treatment Optimizer数字工具,结合用户自定的副作用关切权重,用TOPSIS多准则决策分析对治疗排序并以热图呈现。
要点
- 数据库覆盖32种抗精神病药14类副作用、37种抗抑郁药9类副作用,并揭示规避一种副作用可能增加其他副作用风险的临床困境。
- Psymatik工具将副作用数据库与个体化关切权重结合,经TOPSIS计算后按偏好排序治疗并以热图输出。
- 作者认为该工具支持协作式、个体化、循证的处方决策,有望改善精神科实践与结局。
核心结论
- 抗抑郁药与抗精神病药副作用数据库及Psymatik数字工具可支持协作、个体化、循证的处方决策,有望用于精神科实践并改善结局。
研究设计与样本
- 伞状综述:检索Embase、PsycINFO、 MEDLINE自建库至2023年6月26日,纳入成人(≥18岁)抗精神病药单药治疗精神分裂症或抗抑郁药单药治疗重性抑郁障碍的随机对照试验meta分析,并补充复习国家与国际指南及共识声明。
- 共3724条文献记录中14篇文章(含68项单项副作用meta分析)符合纳入标准;复习19部指南,其中7部提供序数数据。
- 抗精神病药数据来自5项研究(11项meta分析,n=65 594例患者)和4部指南,抗抑郁药数据来自3部指南;最终数据库含32种抗精神病药(14类副作用)和37种抗抑郁药(9类副作用)。
- 效应量取自考察药物数量最多的meta分析;meta分析覆盖不全时依据指南序数排名进行插补,无法插补时提取序数评分;meta分析与序数结局均归一化为0至1之间的值。
- 构建Psymatik Treatment Optimizer数字工具,将副作用数据库与用户副作用关切权重通过TOPSIS多准则决策分析合成,抗抑郁药计算多达5851项两两比较、抗精神病药多达5142项两两比较,输出以热图呈现。
主要发现
- 数据库揭示平衡副作用的临床困境:规避一种副作用(如抗精神病药的体重增加)会增加其他副作用(如静坐不能)的风险。
- Psymatik按个体用户偏好对治疗排序并以热图输出,帮助在副作用权衡中做出选择。
关键数值与推荐
- 纳入标准为成人(≥18岁)、药物有共同对照、考察抗精神病药单药治疗精神分裂症或抗抑郁药单药治疗重性抑郁障碍的随机对照试验meta分析。
- 副作用效应量归一化为0至1之间的值;关切权重与副作用数据库经TOPSIS方法合成。
- 数据库覆盖32种抗精神病药14类副作用和37种抗抑郁药9类副作用。
临床怎么用
- 临床处方时可借助该副作用数据库与Psymatik工具,结合患者对具体副作用的关切程度进行个体化、协作式决策。
- 需注意副作用之间常需权衡,规避某一副作用可能升高其他副作用风险,应与患者讨论这种取舍。
局限性
- 抗抑郁药副作用数据仅来自3部指南,未报告来自meta分析的数据。
- 部分meta分析覆盖不全,数据依赖指南序数排名插补或序数评分提取,并非全部来自直接meta分析证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Side-effects of psychiatric medication impair quality of life and functioning. Furthermore, they contribute to morbidity, mortality, stigma, and poor treatment concordance resulting in relapse of psychiatric illness. Guidelines recommend discussing side-effects with patients when making treatment decisions, but a synthesis of antidepressant and antipsychotic side-effects to guide this process is missing, and considering all side-effects is a complex, multidimensional process. We aimed to create comprehensive databases of antipsychotic and antidepressant side-effects, and a digital tool to support database navigation. METHODS: To create the databases, we did an umbrella review of Embase, PsycINFO, and MEDLINE from database inception to June 26, 2023. We included meta-analyses of randomised controlled trials examining antipsychotic monotherapy in the treatment of schizophrenia or antidepressant monotherapy in the treatment of major depressive disorder. We included meta-analyses in adults (aged ≥18 years) that assessed drugs with a common comparator. The search was complemented by a review of national and international guidelines and consensus statements for the treatment of major depressive disorder and schizophrenia in adults. Effect sizes for antipsychotic and antidepressant side-effects were extracted from meta-analyses examining the largest number of drugs. In cases of incomplete meta-analytic coverage, data were imputed on the basis of guideline-derived ordinal rankings or, if imputation was not possible, ordinal scores were extracted. Both meta-analytic and ordinal outcomes were normalised to provide values between 0 and 1. We then constructed a digital tool, the Psymatik Treatment Optimizer, to combine the side-effect databases with side-effect concerns of an individual user, to enable users to select side-effects of concern and the relative degree of concern for each side-effect. Concern weightings and the side-effect databases are synthesised via a multicriteria decision analysis method (technique for order of preference by similarity to ideal situation, or TOPSIS). FINDINGS: Of 3724 citations, 14 articles containing 68 meta-analyses of individual side-effects met inclusion criteria. After review of 19 guidelines, seven provided ordinal data. Antipsychotic data were extracted from five studies (11 meta-analyses, n=65 594 patients) and four guidelines, and antidepressant data were extracted from three guidelines. The resultant databases included data on 32 antipsychotics (14 side-effects) and 37 antidepressants (nine side-effects). The databases highlighted the clinical dilemma associated with balancing side-effects, with avoidance of one side-effect (eg, weight gain for antipsychotics) increasing the risk of others (eg, akathisia). To aid with this dilemma, the Psymatik Treatment Optimizer synthesises the side-effect databases with individual user-defined concern weights. After computing up to 5851 pairwise comparisons for antidepressants and 5142 pairwise comparisons for antipsychotics, Psymatik ranks treatments in order of preference for the individual user, with the output presented in a heatmap. INTERPRETATION: By facilitating collaborative, personalised, and evidence-based prescribing decisions, the side-effect databases and digital application supports care delivery that is consistent with international regulatory guidance for the treatment of schizophrenia and depression, and it therefore has promise for informing psychiatric practice and improving outcomes. FUNDING: National Institute for Health and Care Research, Maudsley Charity, Wellcome Trust, Medical Research Council.
引用
- Pillinger T, Howes OD, Correll CU, et al. Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development. Lancet Psychiatry. 2023. PMID: 37774723. doi:10.1016/S2215-0366(23)00262-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。